Woodline Partners LP Morphic Holding, Inc. Transaction History

Woodline Partners LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$26.12 - $34.07 $44 Million - $57.3 Million	1,683,202 Added 1683.2%	1,783,202 $60.8 Million
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $2.66 Million - $4.03 Million	100,000 New	100,000 $3.52 Million
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $15.6 Million - $43.4 Million	730,452 Added 147.74%	1,224,881 $28.1 Million
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $4.96 Million - $8.97 Million	144,429 Added 41.27%	494,429 $28.3 Million
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $7.51 Million - $14 Million	-288,552 Reduced 45.19%	350,000 $13.2 Million
Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $15.4 Million - $19.4 Million	638,552 New	638,552 $17.1 Million
Q4 2021 Feb 14, 2022	SELL	$43.27 - $65.72 $939,175 - $1.43 Million	-21,705 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$53.61 - $67.5 $2.03 Million - $2.56 Million	-37,951 Reduced 63.62%	21,705 $1.23 Million
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $1.57 Million - $2.26 Million	34,747 Added 139.5%	59,656 $3.42 Million
Q1 2021 May 17, 2021	BUY	$29.77 - $84.85 $741,540 - $2.11 Million	24,909 New	24,909 $1.58 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.